RECRUITINGOBSERVATIONAL

A Study on Paxlovid Once in the Market, to Observe Its Safety and Effectiveness in Patients Who Have a High Chance of Getting Severe COVID-19

Post Marketing Surveillance to Observe Safety and Effectiveness of PAXLOVID in Patients With Positive Results of Viral Testing, and Who Are at High Risk for Progression to Severe COVID-19

About This Trial

The purpose of this study is to look at the safety and effectiveness of PAXLOVID in the real world and not in clinical studies. The study observes patients who have a high chance of getting severe COVID-19 in Korea. This study is seeking participants who are: * Patients with mild-to-moderate COVID-19 symptoms and at high chance of getting severe COVID-19, including hospitalization or death. * Patients who received, are currently receiving, or are going to receive PAXLOVID according to locally approved label. * Patients who have signed informed consent documents after understanding all the important parts of the study. All participants are treated according to routine medical practice and there are no scheduled visits required by this study. All participants will be studied for a follow-up period of 28 days from the last PAXLOVID treatment to understand the safety and the effectiveness of treatment.

Who May Be Eligible (Plain English)

Who May Qualify: - Patients who received, are currently receiving, or are going to receive PAXLOVID according to locally approved label. - Patients (or a legally acceptable representative) who are willing to provide written willing to sign a consent form/assent prior to study enrollment. Who Should NOT Join This Trial: - Patients with contraindication according to locally approved label of PAXLOVID. - Patients who are going to receive any investigational medicine during the observation period. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * Patients who received, are currently receiving, or are going to receive PAXLOVID according to locally approved label. * Patients (or a legally acceptable representative) who are willing to provide written informed consent/assent prior to study enrollment. Exclusion Criteria: * Patients with contraindication according to locally approved label of PAXLOVID. * Patients who are going to receive any investigational medicine during the observation period.

Locations (1)

Pfizer Korea

Seoul, South Korea